Key result
Higher WHO MPOWER tobacco-control scores linked to ~1 per 100,000 drop in CVD mortality.
Why the study?
Does stronger implementation of WHO MPOWER tobacco control policies reduce tobacco-attributable cardiovascular mortality globally?
Observational (n=148)
Yes
Does stronger implementation of WHO MPOWER tobacco control policies reduce tobacco-attributable cardiovascular mortality globally?
Stronger implementation of WHO MPOWER tobacco control policies is independently associated with substantial reductions in tobacco-attributable cardiovascular mortality worldwide.
Background: Tobacco use remains a leading modifiable driver of cardiovascular disease (CVD) worldwide. The WHO MPOWER framework quantifies national tobacco-control strength, yet longitudinal causal associations with CVD mortality have not been comprehensively quantified across countries. Methods: A longitudinal panel of 148 countries (2007–2022) was assembled integrating: (1) Global Burden of Disease 2023 estimates of age-standardized CVD mortality attributable to tobacco (per 100 000); (2) WHO MPOWER composite scores (0–5 scale, equal-weighted across six policy components); and (3) World Bank GDP per capita (USD). We applied country- and year-fixed-effects linear regression to estimate the association between MPOWER intensity at t–3 and subsequent CVD mortality at year t , adjusting for log-transformed GDP. The three-year lag was selected a priori , consistent with cardiovascular disease latency periods. Robust (HC3) standard errors were clustered by country. Sensitivity analyses tested alternate lag structures (t–1 to t–5), exclusion of outliers (±3 SD or high Cook’s distance), and GDP-by-income-level interaction terms. Results: From 2007–2022, global tobacco-attributable CVD mortality declined from 37.3 to 32.4 per 100 000 (–13.2%), as mean MPOWER strength increased from 2.7 to 2.9. Each one-point increase in lagged MPOWER score was associated with a 1.07 ± 0.20 per 100 000 reduction in CVD mortality ( p < 0.001), independent of GDP ( β = –2.10 ± 0.69; p = 0.002). Over the full MPOWER scale (0→5), this translates to ~5.4 fewer deaths per 100 000, representing a 16% decline at mean baseline mortality. A 1% increase in GDP corresponded to a 0.021 per 100 000 reduction in CVD mortality. Model fit was strong (within-country R 2 = 0.71; total R 2 = 0.97). Income-level interactions were non-significant, indicating consistent MPOWER effects across development contexts. High-policy countries (UK, Australia, Japan, Brazil) achieved steepest declines, while lower-policy countries (Nigeria, Ethiopia, Pakistan) showed limited progress. Conclusions: Stronger MPOWER implementation, sustained over multiple years, is independently associated with substantial reductions in tobacco-attributable CVD mortality worldwide, even after accounting for GDP, year effects, and lag structure. While residual confounding and ecological inference limit causal certainty, these findings provide robust, policy-relevant evidence supporting global intensification of comprehensive tobacco control.
No takes yet. Share an insight, caveat, or question.
Parisapogu et al. (2026) conducted an observational in Cardiovascular disease mortality attributable to tobacco (n=148). WHO MPOWER tobacco-control policies vs. Lower MPOWER score was evaluated on Age-standardized CVD mortality attributable to tobacco (per 100,000) (1.07 per 100,000 reduction per 1-point increase, p=<0.001). Each one-point increase in WHO MPOWER tobacco-control score was associated with a 1.07 per 100,000 reduction in tobacco-attributable cardiovascular mortality (p<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: